Ciprofloxacin (ATC Code J01MA02) is a bactericidal second-generation fluoroquinolone antimicrobial agent that targets bacterial DNA gyrase (topoisomerase II, encoded by gyrA/gyrB) and topoisomerase IV (parC/parE), arresting DNA replication, transcription, and supercoiling.
Clinical Indications & Tissue Penetration
Ciprofloxacin achieves urinary, prostatic, renal parenchymal, and osseous concentrations that significantly exceed simultaneous serum levels:
- Acute Pyelonephritis & Complicated Urinary Tract Infections (cUTI): Oral ciprofloxacin (500 mg PO twice daily for 7 days, or 1,000 mg extended-release daily) achieves high cure rates in culture-confirmed susceptible Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa upper urinary tract infections.
- Chronic Bacterial Prostatitis: Superior lipid solubility across prostatic epithelium (500 mg PO q12h for 28 days).
- Bone, Joint & Intra-Abdominal Infections: Gram-negative osteomyelitis, malignant otitis externa (P. aeruginosa), typhoid fever (Salmonella Typhi), and inhalational anthrax prophylaxis.
Antimicrobial Stewardship & Safety Precautions
In accordance with international infectious disease guidelines, fluoroquinolones should be reserved for complicated infections or culture-proven resistant pathogens rather than empiric uncomplicated cystitis due to rising gyrA QRDR mutations and black-box precautions regarding tendinopathy, peripheral neuropathy, QT prolongation, and aortic aneurysm risk.
• Urinary Tract Infection (UTI) & Acute Pyelonephritis Clinical Guide
• Interpreting Urine Culture Colony Counts & Ciprofloxacin Sensitivity